KRAS biomarker testing disparities in colorectal cancer patients in New Mexico
Open Access
- 20 November 2017
- journal article
- research article
- Published by Elsevier BV in Heliyon
- Vol. 3 (11), e00448
- https://doi.org/10.1016/j.heliyon.2017.e00448
Abstract
No abstract availableFunding Information
- University of New Mexico Department of Surgery
- National Cancer Institute Contract (HHSN2612001300010)
- Task Order
- National Cancer Institute
- University of New Mexico Comprehensive Cancer Center (2P30CA118100-11)
This publication has 40 references indexed in Scilit:
- Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?Genetics in Medicine, 2013
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation StatusJournal of Clinical Oncology, 2011
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyAnnals of Oncology, 2011
- Socioeconomic, Rural-Urban, and Racial Inequalities in US Cancer Mortality: Part I—All Cancers and Lung Cancer and Part II—Colorectal, Prostate, Breast, and Cervical CancersJournal of Cancer Epidemiology, 2011
- How Does Older Age Influence Oncologists' Cancer Management?The Oncologist, 2010
- Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With CetuximabAnnals of Surgery, 2010
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody TherapyJournal of Clinical Oncology, 2009
- KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabAnnals of Oncology, 2008
- Future Supply and Demand for Oncologists : Challenges to Assuring Access to Oncology ServicesJournal of Oncology Practice, 2007
- Prevalence of ras gene mutations in human colorectal cancersNature, 1987